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Abstract 
Background: Randomization is the foundation of any clinical trial involving treatment comparison. It helps mitigate 
selection bias, promotes similarity of treatment groups with respect to important known and unknown confounders, 
and contributes to the validity of statistical tests. Various restricted randomization procedures with different proba‑
bilistic structures and different statistical properties are available. The goal of this paper is to present a systematic 
roadmap for the choice and application of a restricted randomization procedure in a clinical trial.
Methods: We survey available restricted randomization procedures for sequential allocation of subjects in a rand‑
omized, comparative, parallel group clinical trial with equal (1:1) allocation. We explore statistical properties of these 
procedures, including balance/randomness tradeoff, type I error rate and power. We perform head‑to‑head compari‑
sons of different procedures through simulation under various experimental scenarios, including cases when com‑
mon model assumptions are violated. We also provide some real‑life clinical trial examples to illustrate the thinking 
process for selecting a randomization procedure for implementation in practice.
Results: Restricted randomization procedures targeting 1:1 allocation vary in the degree of balance/randomness 
they induce, and more importantly, they vary in terms of validity and efficiency of statistical inference when common 
model assumptions are violated (e.g. when outcomes are affected by a linear time trend; measurement error distribu‑
tion is misspecified; or selection bias is introduced in the experiment). Some procedures are more robust than others. 
Covariate‑adjusted analysis may be essential to ensure validity of the results. Special considerations are required when 
selecting a randomization procedure for a clinical trial with very small sample size.
Conclusions: The choice of randomization design, data analytic technique (parametric or nonparametric), and analy‑
sis strategy (randomization‑based or population model‑based) are all very important considerations. Randomization‑
based tests are robust and valid alternatives to likelihood‑based tests and should be considered more frequently by 
clinical investigators.
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Background
Various research designs can be used to acquire sci-
entific medical evidence. The randomized controlled 
trial (RCT) has been recognized as the most credible 
research design for investigations of the clinical effec-
tiveness of new medical interventions [1, 2]. Evidence 
from RCTs is widely used as a basis for submissions of 
regulatory dossiers in request of marketing authori-
zation for new drugs, biologics, and medical devices. 
Three important methodological pillars of the modern 
RCT include blinding (masking), randomization, and 
the use of control group [3].
While RCTs provide the highest standard of clini-
cal evidence, they are laborious and costly, in terms of 
both time and material resources. There are alterna-
tive designs, such as observational studies with either 
a cohort or case–control design, and studies using 
real world evidence (RWE). When properly designed 
and implemented, observational studies can some-
times produce similar estimates of treatment effects 
to those found in RCTs, and furthermore, such stud-
ies may be viable alternatives to RCTs in many set-
tings where RCTs are not feasible and/or not ethical. 
In the era of big data, the sources of clinically relevant 
data are increasingly rich and include electronic health 
records, data collected from wearable devices, health 
claims data, etc. Big data creates vast opportunities for 
development and implementation of novel frameworks 
for comparative effectiveness research [4], and RWE 
studies nowadays can be implemented rapidly and rela-
tively easily. But how credible are the results from such 
studies?
In 1980, D. P. Byar issued warnings and highlighted 
potential methodological problems with comparison 
of treatment effects using observational databases [5]. 
Many of these issues still persist and actually become 
paramount during the ongoing COVID-19 pandemic 
when global scientific efforts are made to find safe and 
efficacious vaccines and treatments as soon as possi-
ble. While some challenges pertinent to RWE studies 
are related to the choice of proper research methodol-
ogy, some additional challenges arise from increasing 
requirements of health authorities and editorial boards 
of medical journals for the investigators to present 
evidence of transparency and reproducibility of their 
conducted clinical research. Recently, two top medical 
journals, the New England Journal of Medicine and the 
Lancet, retracted two COVID-19 studies that relied on 
observational registry data [6, 7]. The retractions were 
made at the request of the authors who were unable 
to ensure reproducibility of the results [8]. Undoubt-
edly, such cases are harmful in many ways. The already 
approved drugs may be wrongly labeled as “toxic” or 
“inefficacious”, and the reputation of the drug devel-
opers could be blemished or destroyed. Therefore, the 
highest standards for design, conduct, analysis, and 
reporting of clinical research studies are now needed 
more than ever. When treatment effects are modest, yet 
still clinically meaningful, a double-blind, randomized, 
controlled clinical trial design helps detect these dif-
ferences while adjusting for possible confounders and 
adequately controlling the chances of both false posi-
tive and false negative findings.
Randomization in clinical trials has been an important 
area of methodological research in biostatistics since the 
pioneering work of A. Bradford Hill in the 1940’s and 
the first published randomized trial comparing strep-
tomycin with a non-treatment control [9]. Statisticians 
around the world have worked intensively to elaborate 
the value, properties, and refinement of randomization 
procedures with an incredible record of publication [10]. 
In particular, a recent EU-funded project (www. IDeAl. 
rwth- aachen. de) on innovative design and analysis of 
small population trials has “randomization” as one work 
package. In 2020, a group of trial statisticians around the 
world from different sectors formed a subgroup of the 
Drug Information Association (DIA) Innovative Designs 
Scientific Working Group (IDSWG) to raise awareness of 
the full potential of randomization to improve trial qual-
ity, validity and rigor (https:// rando mizat ion- worki ng- 
group. rwth- aachen. de/).
The aims of the current paper are three-fold. First, we 
describe major recent methodological advances in ran-
domization, including different restricted randomiza-
tion designs that have superior statistical properties 
compared to some widely used procedures such as per-
muted block designs. Second, we discuss different types 
of experimental biases in clinical trials and explain how a 
carefully chosen randomization design can mitigate risks 
of these biases. Third, we provide a systematic roadmap 
for evaluating different restricted randomization proce-
dures and selecting an “optimal” one for a particular trial. 
We also showcase application of these ideas through sev-
eral real life RCT examples.
The target audience for this paper would be clinical 
investigators and biostatisticians who are tasked with the 
design, conduct, analysis, and interpretation of clinical 
trial results, as well as regulatory and scientific/medical 
journal reviewers. Recognizing the breadth of the con-
cept of randomization, in this paper we focus on a ran-
domized, comparative, parallel group clinical trial design 
with equal (1:1) allocation, which is typically imple-
mented using some restricted randomization procedure, 
possibly stratified by some important baseline prognostic 
factor(s) and/or study center. Some of our findings and 
recommendations are generalizable to more complex 
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clinical trial settings. We shall highlight these generali-
zations and outline additional important considerations 
that fall outside the scope of the current paper.
The paper is organized as follows. The “Methods” sec-
tion provides some general background on the methodol-
ogy of randomization in clinical trials, describes existing 
restricted randomization procedures, and discusses some 
important criteria for comparison of these procedures in 
practice. In the “Results” section, we present our findings 
from four simulation studies that illustrate the thinking 
process when evaluating different randomization design 
options at the study planning stage. The “Conclusions” 
section summarizes the key findings and important con-
siderations on restricted randomization procedures, and 
it also highlights some extensions and further topics on 
randomization in clinical trials.
Methods
What is randomization and what are its virtues in clinical 
trials?
Randomization is an essential component of an experi-
mental design in general and clinical trials in particular. 
Its history goes back to R. A. Fisher and his classic book 
“The Design of Experiments” [11]. Implementation of 
randomization in clinical trials is due to A. Bradford Hill 
who designed the first randomized clinical trial evaluat-
ing the use of streptomycin in treating tuberculosis in 
1946 [9, 12, 13].
Reference [14] provides a good summary of the ration-
ale and justification for the use of randomization in clini-
cal trials. The randomized controlled trial (RCT) has 
been referred to as “the worst possible design (except for 
all the rest)” [15], indicating that the benefits of randomi-
zation should be evaluated in comparison to what we are 
left with if we do not randomize. Observational studies 
suffer from a wide variety of biases that may not be ade-
quately addressed even using state-of-the-art statistical 
modeling techniques.
The RCT in the medical field has several features that 
distinguish it from experimental designs in other fields, 
such as agricultural experiments. In the RCT, the experi-
mental units are humans, and in the medical field often 
diagnosed with a potentially fatal disease. These subjects 
are sequentially enrolled for participation in the study at 
selected study centers, which have relevant expertise for 
conducting clinical research. Many contemporary clinical 
trials are run globally, at multiple research institutions. 
The recruitment period may span several months or even 
years, depending on a therapeutic indication and the tar-
get patient population. Patients who meet study eligibil-
ity criteria must sign the informed consent, after which 
they are enrolled into the study and, for example, rand-
omized to either experimental treatment E or the control 
treatment C according to the randomization sequence. In 
this setup, the choice of the randomization design must 
be made judiciously, to protect the study from experi-
mental biases and ensure validity of clinical trial results.
The first virtue of randomization is that, in combina-
tion with allocation concealment and masking, it helps 
mitigate selection bias due to an investigator’s potential 
to selectively enroll patients into the study [16]. A non-
randomized, systematic design such as a sequence of 
alternating treatment assignments has a major fallacy: 
an investigator, knowing an upcoming treatment assign-
ment in a sequence, may enroll a patient who, in their 
opinion, would be best suited for this treatment. Conse-
quently, one of the groups may contain a greater number 
of “sicker” patients and the estimated treatment effect 
may be biased. Systematic covariate imbalances may 
increase the probability of false positive findings and 
undermine the integrity of the trial. While randomiza-
tion alleviates the fallacy of a systematic design, it does 
not fully eliminate the possibility of selection bias (unless 
we consider complete randomization for which each 
treatment assignment is determined by a flip of a coin, 
which is rarely, if ever used in practice [17]). Commonly, 
RCTs employ restricted randomization procedures which 
sequentially balance treatment assignments while main-
taining allocation randomness. A popular choice is the 
permuted block design that controls imbalance by mak-
ing treatment assignments at random in blocks. To mini-
mize potential for selection bias, one should avoid overly 
restrictive randomization schemes such as permuted 
block design with small block sizes, as this is very similar 
to alternating treatment sequence.
The second virtue of randomization is its tendency to 
promote similarity of treatment groups with respect to 
important known, but even more importantly, unknown 
confounders. If treatment assignments are made at ran-
dom, then by the law of large numbers, the average values 
of patient characteristics should be approximately equal 
in the experimental and the control groups, and any 
observed treatment difference should be attributed to the 
treatment effects, not the effects of the study participants 
[18]. However, one can never rule out the possibility that 
the observed treatment difference is due to chance, e.g. as 
a result of random imbalance in some patient character-
istics [19]. Despite that random covariate imbalances can 
occur in clinical trials of any size, such imbalances do not 
compromise the validity of statistical inference, provided 
that proper statistical techniques are applied in the data 
analysis.
Several misconceptions on the role of randomization 
and balance in clinical trials were documented and dis-
cussed by Senn [20]. One common misunderstanding 
is that balance of prognostic covariates is necessary 
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for valid inference. In fact, different randomization 
designs induce different extent of balance in the dis-
tributions of covariates, and for a given trial there is 
always a possibility of observing baseline group dif-
ferences. A legitimate approach is to pre-specify in 
the protocol the clinically important covariates to be 
adjusted for in the primary analysis, apply a randomi-
zation design (possibly accounting for selected covari-
ates using pre-stratification or some other approach), 
and perform a pre-planned covariate-adjusted analysis 
(such as analysis of covariance for a continuous pri-
mary outcome), verifying the model assumptions and 
conducting additional supportive/sensitivity analyses, 
as appropriate. Importantly, the pre-specified prog-
nostic covariates should always be accounted for in the 
analysis, regardless whether their baseline differences 
are present or not [20].
It should be noted that some randomization designs 
(such as covariate-adaptive randomization procedures) 
can achieve very tight balance of covariate distributions 
between treatment groups [21]. While we address rand-
omization within pre-specified stratifications, we do not 
address more complex covariate- and response-adaptive 
randomization in this paper.
Finally, randomization plays an important role in sta-
tistical analysis of the clinical trial. The most common 
approach to inference following the RCT is the invoked 
population model [10]. With this approach, one posits 
that there is an infinite target population of patients with 
the disease, from which n eligible subjects are sampled in 
an unbiased manner for the study and are randomized to 
the treatment groups. Within each group, the responses 
are assumed to be independent and identically distrib-
uted (i.i.d.), and inference on the treatment effect is per-
formed using some standard statistical methodology, e.g. 
a two sample t-test for normal outcome data. The added 
value of randomization is that it makes the assumption of 
i.i.d. errors more feasible compared to a non-randomized 
study because it introduces a real element of chance in 
the allocation of patients.
An alternative approach is the randomization model, 
in which the implemented randomization itself forms the 
basis for statistical inference [10]. Under the null hypoth-
esis of the equality of treatment effects, individual out-
comes (which are regarded as not influenced by random 
variation, i.e. are considered as fixed) are not affected by 
treatment. Treatment assignments are permuted in all 
possible ways consistent with the randomization proce-
dure actually used in the trial. The randomization-based 
p-value is the sum of null probabilities of the treat-
ment assignment permutations in the reference set that 
yield the test statistic values greater than or equal to the 
experimental value. A randomization-based test can be a 
useful supportive analysis, free of assumptions of para-
metric tests and protective against spurious significant 
results that may be caused by temporal trends [14, 22].
It is important to note that Bayesian inference has 
also become a common statistical analysis in RCTs [23]. 
Although the inferential framework relies upon subjec-
tive probabilities, a study analyzed through a Bayesian 
framework still relies upon randomization for the other 
aforementioned virtues [24]. Hence, the randomization 
considerations discussed herein have broad application.
What types of randomization methodologies are available?
Randomization is not a single methodology, but a very 
broad class of design techniques for the RCT [10]. In 
this paper, we consider only randomization designs for 
sequential enrollment clinical trials with equal (1:1) allo-
cation in which randomization is not adapted for covari-
ates and/or responses. The simplest procedure for an 
RCT is complete randomization design (CRD) for which 
each subject’s treatment is determined by a flip of a fair 
coin [25]. CRD provides no potential for selection bias 
(e.g. based on prediction of future assignments) but it can 
result, with non-negligible probability, in deviations from 
the 1:1 allocation ratio and covariate imbalances, espe-
cially in small samples. This may lead to loss of statistical 
efficiency (decrease in power) compared to the balanced 
design. In practice, some restrictions on randomization 
are made to achieve balanced allocation. Such randomi-
zation designs are referred to as restricted randomization 
procedures [26, 27].
Suppose we plan to randomize an even number of sub-
jects n sequentially between treatments E and C. Two 
basic designs that equalize the final treatment numbers 
are the random allocation rule (Rand) and the truncated 
binomial design (TBD), which were discussed in the 
1957 paper by Blackwell and Hodges [28]. For Rand, any 
sequence of exactly n/2 E’s and n/2 C’s is equally likely. 
For TBD, treatment assignments are made with prob-
ability 0.5 until one of the treatments receives its quota 
of n/2 subjects; thereafter all remaining assignments are 
made deterministically to the opposite treatment.
A common feature of both Rand and TBD is that 
they aim at the final balance, whereas at intermedi-
ate steps it is still possible to have substantial imbal-
ances, especially if n is large. A long run of a single 
treatment in a sequence may be problematic if there 
is a time drift in some important covariate, which can 
lead to chronological bias [29]. To mitigate this risk, 
one can further restrict randomization so that treat-
ment assignments are balanced over time. One com-
mon approach is the permuted block design (PBD) [30], 
for which random treatment assignments are made 
in blocks of size 2b ( b is some small positive integer), 
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with exactly b allocations to each of the treatments E 
and C. The PBD is perhaps the oldest (it can be traced 
back to A. Bradford Hill’s 1951 paper [12]) and the 
most widely used randomization method in clinical tri-
als. Often its choice in practice is justified by simplicity 
of implementation and the fact that it is referenced in 
the authoritative ICH E9 guideline on statistical prin-
ciples for clinical trials [31]. One major challenge with 
PBD is the choice of the block size. If b = 1 , then every 
pair of allocations is balanced, but every even alloca-
tion is deterministic. Larger block sizes increase allo-
cation randomness. The use of variable block sizes has 
been suggested [31]; however, PBDs with variable block 
sizes are also quite predictable [32]. Another problem-
atic feature of the PBD is that it forces periodic return 
to perfect balance, which may be unnecessary from the 
statistical efficiency perspective and may increase the 
risk of prediction of upcoming allocations.
More recent and better alternatives to the PBD are 
the maximum tolerated imbalance (MTI) procedures 
[33–41]. These procedures provide stronger encryp-
tion of the randomization sequence (i.e. make it more 
difficult to predict future treatment allocations in the 
sequence even knowing the current sizes of the treat-
ment groups) while controlling treatment imbalance 
at a pre-defined threshold throughout the experiment. 
A general MTI procedure specifies a certain bound-
ary for treatment imbalance, say b > 0 , that cannot 
be exceeded. If, at a given allocation step the absolute 
value of imbalance is equal to b , then one next alloca-
tion is deterministically forced toward balance. This 
is in contrast to PBD which, after reaching the target 
quota of allocations for either treatment within a block, 
forces all subsequent allocations to achieve perfect bal-
ance at the end of the block. Some notable MTI pro-
cedures are the big stick design (BSD) proposed by 
Soares and Wu in 1983 [37], the maximal procedure 
proposed by Berger, Ivanova and Knoll in 2003 [35], the 
block urn design (BUD) proposed by Zhao and Weng 
in 2011 [40], just to name a few. These designs control 
treatment imbalance within pre-specified limits and are 
more immune to selection bias than the PBD [42, 43].
Another important class of restricted randomization 
procedures is biased coin designs (BCDs). Starting with 
the seminal 1971 paper of Efron [44], BCDs have been 
a hot research topic in biostatistics for 50 years. Efron’s 
BCD is very simple: at any allocation step, if treat-
ment numbers are balanced, the next assignment is 
made with probability 0.5; otherwise, the underrepre-
sented treatment is assigned with probability p , where 
0.5 < p ≤ 1 is a fixed and pre-specified parameter that 
determines the tradeoff between balance and random-
ness. Note that p = 1 corresponds to PBD with block 
size 2. If we set p < 1 (e.g. p = 2/3 ), then the proce-
dure has no deterministic assignments and treatment 
allocation will be concentrated around 1:1 with high 
probability [44]. Several extensions of Efron’s BCD pro-
viding better tradeoff between treatment balance and 
allocation randomness have been proposed [45–49]; for 
example, a class of adjustable biased coin designs intro-
duced by Baldi Antognini and Giovagnoli in 2004 [49] 
unifies many BCDs in a single framework. A compre-
hensive simulation study comparing different BCDs has 
been published by Atkinson in 2014 [50].
Finally, urn models provide a useful mechanism for 
RCT designs [51]. Urn models apply some probabilis-
tic rules to sequentially add/remove balls (representing 
different treatments) in the urn, to balance treatment 
assignments while maintaining the randomized nature of 
the experiment [39, 40, 52–55]. A randomized urn design 
for balancing treatment assignments was proposed by 
Wei in 1977 [52]. More novel urn designs, such as the 
drop-the-loser urn design developed by Ivanova in 2003 
[55] have reduced variability and can attain the target 
treatment allocation more efficiently. Many urn designs 
involve parameters that can be fine-tuned to obtain ran-
domization procedures with desirable balance/random-
ness tradeoff [56].
What are the attributes of a good randomization 
procedure?
A “good” randomization procedure is one that helps suc-
cessfully achieve the study objective(s). Kalish and Begg 
[57] state that the major objective of a comparative clini-
cal trial is to provide a precise and valid comparison. To 
achieve this, the trial design should be such that it: 1) 
prevents bias; 2) ensures an efficient treatment compar-
ison; and 3) is simple to implement to minimize opera-
tional errors. Table 1 elaborates on these considerations, 
focusing on restricted randomization procedures for 1:1 
randomized trials.
Before delving into a detailed discussion, let us intro-
duce some important definitions. Following [10], a rand-
omization sequence is a random vector δn = (δ1, . . . , δn) , 
where δi = 1 , if the ith subject is assigned to treat-
ment E or δi = 0 , if the i th subject is assigned to treat-
ment C. A restricted randomization procedure can be 
defined by specifying a probabilistic rule for the treat-
ment assignment of the (i+1)st subject, δi+1 , given 
the past allocations δi for i ≥ 1 . Let NE(i) =
∑i
j=1δj 
and NC(i) = i − NE(i) denote the numbers of subjects 
assigned to treatments E and C, respectively, after i allo-
cation steps. Then D(i) = NE(i)− NC(i) is treatment 
imbalance after i allocations. For any i ≥ 1 , D(i) is a 
random variable whose probability distribution is deter-
mined by the chosen randomization procedure.
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Balance and randomness
Treatment balance and allocation randomness are 
two competing requirements in the design of an RCT. 
Restricted randomization procedures that provide a good 
tradeoff between these two criteria are desirable in practice.
Consider a trial with sample size n . The absolute value 
of imbalance, |D(i)| (i = 1, . . . , n) , provides a measure of 
deviation from equal allocation after i allocation steps. 
|D(i)| = 0 indicates that the trial is perfectly balanced. 
One can also consider Pr(|D(i)| = 0) , the probability of 
achieving exact balance after i allocation steps. In par-
ticular Pr(|D(n)| = 0) is the probability that the final 
treatment numbers are balanced. Two other useful sum-
mary measures are the expected imbalance at the ith step, 
E|D(i)| and the expected value of the maximum imbal-








Greater forcing of balance implies lack of randomness. 
A procedure that lacks randomness may be suscepti-
ble to selection bias [16], which is a prominent issue in 
open-label trials with a single center or with randomi-
zation stratified by center, where the investigator knows 
the sequence of all previous treatment assignments. A 
classic approach to quantify the degree of susceptibility 
of a procedure to selection bias is the Blackwell-Hodges 
model [28]. Let Gi = 1 (or 0), if at the ith allocation step 
an investigator makes a correct (or incorrect) guess on 
treatment assignment δi , given past allocations δi−1 . 
Then the predictability of the design at the ith step is the 
expected value of Gi , i.e. E(Gi) = Pr(Gi = 1) . Blackwell 
and Hodges [28] considered the expected bias factor, 
the difference between expected total number of correct 
guesses of a given sequence of random assignments and 
the similar quantity obtained from CRD for which treat-
ment assignments are made independently with equal 




− n/2 . This quantity is 
zero for CRD, and it is positive for restricted randomiza-
tion procedures (greater values indicate higher expected 
bias). Matts and Lachin [30] suggested taking expected 
proportion of deterministic assignments in a sequence as 
another measure of lack of randomness.
In the literature, various restricted randomization 
procedures have been compared in terms of balance 
and randomness [50, 58, 59]. For instance, Zhao et  al. 
[58] performed a comprehensive simulation study of 
14 restricted randomization procedures with different 
choices of design parameters, for sample sizes in the 
range of 10 to 300. The key criteria were the maximum 
absolute imbalance and the correct guess probability. 
The authors found that the performance of the designs 
was within a closed region with the boundaries shaped 
by Efron’s BCD [44] and the big stick design [37], sig-
nifying that the latter procedure with a suitably chosen 
MTI boundary can be superior to other restricted ran-
domization procedures in terms of balance/random-
ness tradeoff. Similar findings confirming the utility of 
the big stick design were recently reported by Hilgers 
et al. [60].
Validity and efficiency
Validity of a statistical procedure essentially means that 
the procedure provides correct statistical inference fol-
lowing an RCT. In particular, a chosen statistical test is 
valid, if it controls the chance of a false positive finding, 
that is, the pre-specified probability of a type I error of 
the test is achieved but not exceeded. The strong control 
of type I error rate is a major prerequisite for any con-
firmatory RCT. Efficiency means high statistical power 
for detecting meaningful treatment differences (when 
they exist), and high accuracy of estimation of treatment 
effects.
Both validity and efficiency are major requirements of 
any RCT, and both of these aspects are intertwined with 
treatment balance and allocation randomness. Restricted 
randomization designs, when properly implemented, 
provide solid ground for valid and efficient statistical 
inference. However, a careful consideration of different 
options can help an investigator to optimize the choice of 
a randomization procedure for their clinical trial.
Let us start with statistical efficiency. Equal (1:1) allo-
cation frequently maximizes power and estimation pre-
cision. To illustrate this, suppose the primary outcomes 
Table 1 Considerations for the choice of a restricted randomization procedure
Objective Desired feature(s) of a randomization procedure
Mitigate potential for selection bias A procedure should have high degree of randomness.
Mitigate potential for chronological bias. A procedure should balance treatment assignments over time.
Valid and efficient treatment comparison A procedure should have established statistical properties, provide strong control of false posi‑
tive rate and yield unbiased, low variance estimates of the treatment difference.
A procedure should preserve the unconditional allocation ratio (e.g. 1:1) at every allocation 
step and achieve approximately or exactly the target sample sizes per group.
Ease of implementation Validated statistical software for implementing a randomization procedure must be in place.
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in the two groups are normally distributed with respec-
tive means µE and µC and common standard deviation 
σ > 0 . Then the variance of an efficient estimator of 




where Ln = |D(n)|
2
n  is referred to as loss [61]. Clearly, V  is 
minimized when Ln = 0 , or equivalently, D(n) = 0 , i.e. 
the balanced trial.
When the primary outcome follows a more complex 
statistical model, optimal allocation may be unequal 
across the treatment groups; however, 1:1 allocation is 
still nearly optimal for binary outcomes [62, 63], survival 
outcomes [64], and possibly more complex data types 
[65, 66]. Therefore, a randomization design that balances 
treatment numbers frequently promotes efficiency of the 
treatment comparison.
As regards inferential validity, it is important to dis-
tinguish two approaches to statistical inference after the 
RCT – an invoked population model and a randomization 
model [10]. For a given randomization procedure, these 
two approaches generally produce similar results when 
the assumption of normal random sampling (and some 
other assumptions) are satisfied, but the randomization 
model may be more robust when model assumptions are 
violated; e.g. when outcomes are affected by a linear time 
trend [67, 68]. Another important issue that may inter-
fere with validity is selection bias. Some authors showed 
theoretically that PBDs with small block sizes may result 
in serious inflation of the type I error rate under a selec-
tion bias model [69–71]. To mitigate risk of selection bias, 
one should ideally take preventative measures, such as 
blinding/masking, allocation concealment, and avoidance 
of highly restrictive randomization designs. However, 
for already completed studies with evidence of selection 
bias [72], special statistical adjustments are warranted to 
ensure validity of the results [73–75].
Implementation aspects
With the current state of information technology, imple-
mentation of randomization in RCTs should be straight-
forward. Validated randomization systems are emerging, 
and they can handle randomization designs of increasing 
complexity for clinical trials that are run globally. How-
ever, some important points merit consideration.
The first point has to do with how a randomization 
sequence is generated and implemented. One should 
distinguish between advance and adaptive randomiza-
tion [16]. Here, by “adaptive” randomization we mean 
“in-real-time” randomization, i.e. when a randomization 
sequence is generated not upfront, but rather sequen-
tially, as eligible subjects enroll into the study. Restricted 
randomization procedures are “allocation-adaptive”, in 
the sense that the treatment assignment of an individual 
subject is adapted to the history of previous treatment 
assignments. While in practice the majority of trials with 
restricted and stratified randomization use randomiza-
tion schedules pre-generated in advance, there are some 
circumstances under which “in-real-time” randomiza-
tion schemes may be preferred; for instance, clinical trials 
with high cost of goods and/or shortage of drug supply 
[76].
The advance randomization approach includes the fol-
lowing steps: 1) for the chosen randomization design and 
sample size n , specify the probability distribution on the 
reference set by enumerating all feasible randomization 
sequences of length n and their corresponding prob-
abilities; 2) select a sequence at random from the refer-
ence set according to the probability distribution; and 3) 
implement this sequence in the trial. While enumeration 
of all possible sequences and their probabilities is feasible 
and may be useful for trials with small sample sizes, the 
task becomes computationally prohibitive (and unneces-
sary) for moderate or large samples. In practice, Monte 
Carlo simulation can be used to approximate the prob-
ability distribution of the reference set of all randomiza-
tion sequences for a chosen randomization procedure.
A limitation of advance randomization is that a 
sequence of treatment assignments must be generated 
upfront, and proper security measures (e.g. blinding/
masking) must be in place to protect confidentiality of 
the sequence. With the adaptive or “in-real-time” rand-
omization, a sequence of treatment assignments is gen-
erated dynamically as the trial progresses. For many 
restricted randomization procedures, the randomization 
rule can be expressed as Pr(δi+1 = 1) = |F{D(i)}| , where 
F{·} is some non-increasing function of D(i) for any i ≥ 1 . 
This is referred to as the Markov property [77], which 
makes a procedure easy to implement sequentially. Some 
restricted randomization procedures, e.g. the maximal 
procedure [35], do not have the Markov property.
The second point has to do with how the final data anal-
ysis is performed. With an invoked population model, 
the analysis is conditional on the design and the rand-
omization is ignored in the analysis. With a randomiza-
tion model, the randomization itself forms the basis for 
statistical inference. Reference [14] provides a contem-
poraneous overview of randomization-based inference 
in clinical trials. Several other papers provide important 
technical details on randomization-based tests, includ-
ing justification for control of type I error rate with these 
tests [22, 78, 79]. In practice, Monte Carlo simulation can 
be used to estimate randomization-based p-values [10].
A roadmap for comparison of restricted randomization 
procedures
The design of any RCT starts with formulation of the trial 
objectives and research questions of interest [3, 31]. The 
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choice of a randomization procedure is an integral part 
of the study design. A structured approach for select-
ing an appropriate randomization procedure for an RCT 
was proposed by Hilgers et al. [60]. Here we outline the 
thinking process one may follow when evaluating differ-
ent candidate randomization procedures. Our presented 
roadmap is by no means exhaustive; its main purpose is 
to illustrate the logic behind some important considera-
tions for finding an “optimal” randomization design for 
the given trial parameters.
Throughout, we shall assume that the study is designed 
as a randomized, two-arm comparative trial with 1:1 allo-
cation, with a fixed sample size n that is pre-determined 
based on budgetary and statistical considerations to 
obtain a definitive assessment of the treatment effect via 
the pre-defined hypothesis testing. We start with some 
general considerations which determine the study design:
• Sample size (n). For small or moderate studies, exact 
attainment of the target numbers per group may 
be essential, because even slight imbalance may 
decrease study power. Therefore, a randomization 
design in such studies should equalize well the final 
treatment numbers. For large trials, the risk of major 
imbalances is less of a concern, and more random 
procedures may be acceptable.
• The length of the recruitment period and the trial 
duration. Many studies are short-term and enroll 
participants fast, whereas some other studies are 
long-term and may have slow patient accrual. In the 
latter case, there may be time drifts in patient charac-
teristics, and it is important that the randomization 
design balances treatment assignments over time.
• Level of blinding (masking): double-blind, single-
blind, or open-label. In double-blind studies with 
properly implemented allocation concealment the 
risk of selection bias is low. By contrast, in open-label 
studies the risk of selection bias may be high, and the 
randomization design should provide strong encryp-
tion of the randomization sequence to minimize pre-
diction of future allocations.
• Number of study centers. Many modern RCTs are 
implemented globally at multiple research institu-
tions, whereas some studies are conducted at a single 
institution. In the former case, the randomization is 
often stratified by center and/or clinically important 
covariates. In the latter case, especially in single-insti-
tution open-label studies, the randomization design 
should be chosen very carefully, to mitigate the risk 
of selection bias.
An important point to consider is calibration of the 
design parameters. Many restricted randomization 
procedures involve parameters, such as the block size 
in the PBD, the coin bias probability in Efron’s BCD, the 
MTI threshold, etc. By fine-tuning these parameters, 
one can obtain designs with desirable statistical proper-
ties. For instance, references [80, 81] provide guidance 
on how to justify the block size in the PBD to mitigate 
the risk of selection bias or chronological bias. Refer-
ence [82] provides a formal approach to determine the 
“optimal” value of the parameter p in Efron’s BCD in 
both finite and large samples. The calibration of design 
parameters can be done using Monte Carlo simulations 
for the given trial setting.
Another important consideration is the scope of rand-
omization procedures to be evaluated. As we mentioned 
already, even one method may represent a broad class 
of randomization procedures that can provide differ-
ent levels of balance/randomness tradeoff; e.g. Efron’s 
BCD covers a wide spectrum of designs, from PBD(2) 
(if p = 1 ) to CRD (if p = 0.5 ). One may either prefer to 
focus on finding the “optimal” parameter value for the 
chosen design, or be more general and include various 
designs (e.g. MTI procedures, BCDs, urn designs, etc.) 
in the comparison. This should be done judiciously, on 
a case-by-case basis, focusing only on the most reason-
able procedures. References [50, 58, 60] provide good 
examples of simulation studies to facilitate comparisons 
among various restricted randomization procedures for 
a 1:1 RCT.
In parallel with the decision on the scope of randomi-
zation procedures to be assessed, one should decide upon 
the performance criteria against which these designs 
will be compared. Among others, one might think about 
the two competing considerations: treatment balance 
and allocation randomness. For a trial of size n , at each 
allocation step i = 1, . . . , n one can calculate expected 
absolute imbalance E|D(i)| and the probability of cor-
rect guess Pr(Gi = 1) as measures of lack of balance and 
lack of randomness, respectively. These measures can be 
either calculated analytically (when formulae are avail-
able) or through Monte Carlo simulations. Sometimes it 
may be useful to look at cumulative measures up to the 












j=1Pr(Gj = 1) is the 
average correct guess probability for a design with sam-
ple size n . It is also helpful to visualize the selected crite-
ria. Visualizations can be done in a number of ways; e.g. 
plots of a criterion vs. allocation step, admissibility plots 
of two chosen criteria [50, 59], etc. Such visualizations 
can help evaluate design characteristics, both overall and 
at intermediate allocation steps. They may also provide 
insights into the behavior of a particular design for dif-
ferent values of the tuning parameter, and/or facilitate a 
comparison among different types of designs.
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Another way to compare the merits of different rand-
omization procedures is to study their inferential char-
acteristics such as type I error rate and power under 
different experimental conditions. Sometimes this can 
be done analytically, but a more practical approach is to 
use Monte Carlo simulation. The choice of the modeling 
and analysis strategy will be context-specific. Here we 
outline some considerations that may be useful for this 
purpose:
• Data generating mechanism. To simulate individ-
ual outcome data, some plausible statistical model 
must be posited. The form of the model will depend 
on the type of outcomes (e.g. continuous, binary, 
time-to-event, etc.), covariates (if applicable), the 
distribution of the measurement error terms, and 
possibly some additional terms representing selec-
tion and/or chronological biases [60].
• True treatment effects. At least two scenarios should 
be considered: under the null hypothesis ( H0 : treat-
ment effects are the same) to evaluate the type I error 
rate, and under an alternative hypothesis ( H1 : there 
is some true clinically meaningful difference between 
the treatments) to evaluate statistical power.
• Randomization designs to be compared. The choice 
of candidate randomization designs and their param-
eters must be made judiciously.
• Data analytic strategy. For any study design, one 
should pre-specify the data analysis strategy to 
address the primary research question. Statistical 
tests of significance to compare treatment effects 
may be parametric or nonparametric, with or with-
out adjustment for covariates.
• The approach to statistical inference: population 
model-based or randomization-based. These two 
approaches are expected to yield similar results when 
the population model assumptions are met, but they 
may be different if some assumptions are violated. 
Randomization-based tests following restricted rand-
omization procedures will control the type I error at 
the chosen level if the distribution of the test statistic 
under the null hypothesis is fully specified by the ran-
domization procedure that was used for patient allo-
cation. This is always the case unless there is a major 
flaw in the design (such as selection bias whereby the 
outcome of any individual participant is dependent on 
treatment assignments of the previous participants).
Overall, there should be a well-thought plan captur-
ing the key questions to be answered, the strategy to 
address them, the choice of statistical software for sim-
ulation and visualization of the results, and other rel-
evant details.
Results
In this section we present four examples that illustrate 
how one may approach evaluation of different randomi-
zation design options at the study planning stage. Exam-
ple 1 is based on a hypothetical 1:1 RCT with n = 50 and 
a continuous primary outcome, whereas Examples 2, 3, 
and 4 are based on some real RCTs.
Example 1: Which restricted randomization procedures are 
robust and efficient?
Our first example is a hypothetical RCT in which the 
primary outcome is assumed to be normally distributed 
with mean µE for treatment E, mean µC for treatment C, 
and common variance σ 2 . A total of n subjects are to be 
randomized equally between E and C, and a two-sam-
ple t-test is planned for data analysis. Let � = µE − µC 
denote the true mean treatment difference. We are 
interested in testing a hypothesis H0 :  = 0 (treatment 
effects are the same) vs. H1 :  �= 0.
The total sample size n to achieve given power at some 
clinically meaningful treatment difference c while main-
taining the chance of a false positive result at level α can 
be obtained using standard statistical methods [83]. For 
instance, if �c/σ = 0.95 , then a design with n = 50 sub-
jects (25 per arm) provides approximately 91% power of a 
two-sample t-test to detect a statistically significant treat-
ment difference using 2-sided α = 5%. We shall consider 
12 randomization procedures to sequentially randomize 
n = 50 subjects in a 1:1 ratio.
 1. Random allocation rule – Rand.
 2. Truncated binomial design – TBD.
 3. Permuted block design with block size of 2 – 
PBD(2).
 4. Permuted block design with block size of 4 – 
PBD(4).
 5. Big stick design [37] with MTI = 3 – BSD(3).
 6. Biased coin design with imbalance tolerance [38] 
with p = 2/3 and MTI = 3 – BCDWIT(2/3, 3).
 7. Efron’s biased coin design [44] with p = 2/3 – 
BCD(2/3).
 8. Adjustable biased coin design [49] with a = 2 – 
ABCD(2).
 9. Generalized biased coin design (GBCD) with γ = 1 
[45] – GBCD(1).
 10. GBCD with γ = 2 [46] – GBCD(2).
 11. GBCD with γ = 5 [47] – GBCD(5).
 12. Complete randomization design – CRD.
These 12 procedures can be grouped into five major 
types. I) Procedures 1, 2, 3, and 4 achieve exact final bal-
ance for a chosen sample size (provided the total sample 
size is a multiple of the block size). II) Procedures 5 and 
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6 ensure that at any allocation step the absolute value of 
imbalance is capped at MTI = 3. III) Procedures 7 and 8 
are biased coin designs that sequentially adjust randomiza-
tion according to imbalance measured as the difference in 
treatment numbers. IV) Procedures 9, 10, and 11 (GBCD’s 
with γ = 1, 2, and 5) are adaptive biased coin designs, 
for which randomization probability is modified accord-
ing to imbalance measured as the difference in treatment 
allocation proportions (larger γ implies greater forcing of 
balance). V) Procedure 12 (CRD) is the most random pro-
cedure that achieves balance for large samples.
Balance/randomness tradeoff
We first compare the procedures with respect to treatment 
balance and allocation randomness. To quantify imbalance 
after i allocations, we consider two measures: expected 
value of absolute imbalance E|D(i)| , and expected value 
of loss E(Li) = E|D(i)|2/i [50, 61]. Importantly, for pro-
cedures 1, 2, and 3 the final imbalance is always zero, thus 
E|D(n)| ≡ 0 and E(Ln) ≡ 0 , but at intermediate steps one 
may have E|D(i)| > 0 and E(Li) > 0 , for 1 ≤ i < n . For 
procedures 5 and 6 with MTI = 3, E(Li) ≤ 9/i . For pro-
cedures 7 and 8, E(Ln) tends to zero as n → ∞ [49]. For 
procedures 9, 10, 11, and 12, as n → ∞ , E(Ln) tends to the 
positive constants 1/3, 1/5, 1/11, and 1, respectively [47]. 
We take the cumulative average loss after n allocations as an 
aggregate measure of imbalance: Imb(n) = 1n
∑n
i=1E(Li) , 
which takes values in the 0–1 range.
To measure lack of randomness, we consider two meas-
ures: expected proportion of correct guesses up to the 
ith  step, PCG(i) = 1i
∑i
j=1 Pr(Gj = 1),  i = 1, . . . , n , and 
the forcing index [47, 84], FI(i) =
∑i
j=1E|φj−0.5|
i/4  , where 
E
∣∣φj − 0.5
∣∣ is the expected deviation of the conditional 
probability of treatment E assignment at the jth  alloca-
tion step ( φj ) from the unconditional target value of 0.5. 
Note that PCG(i) takes values in the range from 0.5 for 
CRD to 0.75 for PBD(2) assuming i is even, whereas FI(i) 
takes values in the 0–1 range. At the one extreme, we 
have CRD for which FI(i) ≡ 0 because for CRD φi = 0.5 
for any i ≥ 1 . At the other extreme, we have PBD(2) for 
which every odd allocation is made with probability 0.5, 
and every even allocation is deterministic, i.e. made with 
probability 0 or 1. For PBD(2), assuming i is even, there 
are exactly i/2 pairs of allocations, and so ∑i
j=1E
∣∣φj − 0.5
∣∣ = 0.5 · i/2 = i/4 , which implies that 
FI(i) = 1 for PBD(2). For all other restricted randomiza-
tion procedures one has 0 < FI(i) < 1.
A “good” randomization procedure should have low val-
ues of both loss and forcing index. Different randomization 
procedures can be compared graphically. As a balance/ran-
domness tradeoff metric, one can calculate the quadratic 






2 (in our example n = 50 ), and 
the randomization designs can then be ranked such that 
designs with lower values of d(n) are preferable.
We ran a simulation study of the 12 randomization 
procedures for an RCT with n = 50 . Monte Carlo aver-
age values of absolute imbalance, loss, Imb(i) , FI(i) , and 
d(i) were calculated for each intermediate allocation step 
( i = 1, . . . , 50 ), based on 10,000 simulations.
Figure  1 is a plot of expected absolute imbalance vs. 
allocation step. CRD, GBCD(1), and GBCD(2) show 
increasing patterns. For TBD and Rand, the final imbal-
ance (when n = 50 ) is zero; however, at intermediate 
steps is can be quite large. For other designs, absolute 
imbalance is expected to be below 2 at any allocation step 
up to n = 50 . Note the periodic patterns of PBD(2) and 
PBD(4); for instance, for PBD(2) imbalance is 0 (or 1) for 
any even (or odd) allocation.
Figure  2 is a plot of expected proportion of correct 
guesses vs. allocation step. One can observe that for CRD 
it is a flat pattern at 0.5; for PBD(2) it fluctuates while 
reaching the upper limit of 0.75 at even allocation steps; 
and for ten other designs the values of proportion of cor-
rect guesses fall between those of CRD and PBD(2). The 
TBD has the same behavior up to ~  40th allocation step, 
at which the pattern starts increasing. Rand exhibits an 
increasing pattern with overall fewer correct guesses 
compared to other randomization procedures. Interest-
ingly, BSD(3) is uniformly better (less predictable) than 
ABCD(2), BCD(2/3), and BCDWIT(2/3, 3). For the three 
GBCD procedures, there is a rapid initial increase fol-
lowed by gradual decrease in the pattern; this makes good 
sense, because GBCD procedures force greater balance 
when the trial is small and become more random (and less 
prone to correct guessing) as the sample size increases.
Table 2 shows the ranking of the 12 designs with respect 






for n = 50 . BSD(3), GBCD(2) and GBCD(1) are the top 
three procedures, whereas PBD(2) and CRD are at the bot-
tom of the list.
Figure 3 is a plot of FI(n) vs. Imb(n) for n = 50 . One can see 
the two extremes: CRD that takes the value (0,1), and PBD(2) 
with the value (1,0). The other ten designs are closer to (0,0).
Figure  4 is a heat map plot of the metric d(i) for 
i = 1, . . . , 50 . BSD(3) seems to provide overall best tradeoff 
between randomness and balance throughout the study.
Inferential characteristics: type I error rate and power
Our next goal is to compare the chosen randomization 
procedures in terms of validity (control of the type I 
error rate) and efficiency (power). For this purpose, we 
assumed the following data generating mechanism: for 
the ith subject, conditional on the treatment assignment 
δi , the outcome Yi is generated according to the model
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where ui is an unknown term associated with the 
ith subject and εi ’s are i.i.d. measurement errors. We shall 
explore the following four models:
• M1: Normal random sampling: ui ≡ 0 and εi ∼ i.i.d. 
N(0,1), i = 1, . . . , n . This corresponds to a standard 
setup for a two-sample t-test under a population 
model.
• M2: Linear trend:  ui = 5in+1 and εi ∼ i.i.d. N(0,1), 
i = 1, . . . , n . In this model, the outcomes are affected 
by a linear trend over time [67].
• M3: Cauchy errors: ui ≡ 0 and εi ∼ i.i.d. Cauchy(0,1), 
i = 1, . . . , n . In this setup, we have a misspecification 
of the distribution of measurement errors.
• M4: Selection bias:  ui+1 = −ν · sign{D(i)} , 
i = 0, . . . , n− 1 , with the convention that D(0) = 0 . 
Here, ν > 0 is the “bias effect” (in our simula-
tions we set ν = 0.5 ). We also assume that εi ∼ 
i.i.d. N(0,1), i = 1, . . . , n . In this setup, at each 
allocation step the investigator attempts to intel-
ligently guess the upcoming treatment assignment 
(1)Yi = δiµE + (1− δi)µC + ui + εi, i = 1, . . . , n and selectively enroll a patient who, in their view, would be most suitable for the upcoming treat-
ment. The investigator uses the “convergence” 
guessing strategy [28], that is, guess the treatment 
as one that has been less frequently assigned thus 
far, or make a random guess in case the current 
treatment numbers are equal. Assuming that the 
investigator favors the experimental treatment and 
is interested in demonstrating its superiority over 
the control, the biasing mechanism is as follows: at 
the (i + 1) st step, a “healthier” patient is enrolled, if 
D(i) < 0 ( ui+1 = 0.5 ); a “sicker” patient is enrolled, 
if D(i) > 0 ( ui+1 = −0.5 ); or a “regular” patient is 
enrolled, if D(i) = 0 ( ui+1 = 0).
We consider three statistical test procedures:





















(1 − i)Yi 




NC(n) = n− NE(n) are the observed group sample 
Fig. 1 Simulated expected absolute imbalance vs. allocation step for 12 restricted randomization procedures for n = 50. Note: PBD(2) and PBD(4) 
have forced periodicity absolute imbalance of 0, which distinguishes them from MTI procedures
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Then H0 :  = 0 is rejected at level α , if |t| > t1− α2 ,n−2 , 
the 100(1− α2)th percentile of the t-distribution with 
n− 2 degrees of freedom.
• T2: Randomization-based test using mean dif-
ference: Let δobs and yobs denote, respectively the 
observed sequence of treatment assignments and 
responses, obtained from the trial using randomiza-
tion procedure R . We first compute the observed 




= Y E − YC . 
Then we use Monte Carlo simulation to generate 
L randomization sequences of length n using pro-
cedure R , where L is some large number. For the 
ℓth generated sequence, δℓ , compute Sℓ = S(δℓ, yobs) , 
where ℓ = 1, . . . , L . The proportion of sequences for 
which Sℓ is at least as extreme as Sobs is computed as 
P̂ = 1L
∑L
ℓ=11{|Sℓ| ≥ |Sobs|} . Statistical significance is 
declared, if P̂ < α.
• T3: Randomization-based test based on ranks: 
This test procedure follows the same logic as T2, 
except that the test statistic is calculated based 
on ranks. Given the vector of observed responses 
yobs = (y1, . . . , yn) , let ajn denote the rank of yj 
among the elements of yobs . Let an denote the aver-
age of ajn’s, and let an = (a1n − an, ...,αnn − an)′ . 






Fig. 2 Simulated expected proportion of correct guesses vs. allocation step for 12 restricted randomization procedures for n = 50
Table 2 Ranking of 12 restricted randomization procedures with 
respect to balance/randomness tradeoff for a trial with n = 50 
subjects
Rank Design Imb(n) FI(n) d(n)
1 BSD(3) 0.226 0.316 0.389
2 GBCD(2) 0.220 0.344 0.409
3 GBCD(1) 0.341 0.240 0.417
4 ABCD(2) 0.170 0.419 0.452
5 GBCD(5) 0.121 0.522 0.536
6 BCD(2/3) 0.233 0.487 0.540
7 BCDWIT(2/3, 3) 0.148 0.560 0.579
8 Rand 0.505 0.318 0.597
9 PBD(4) 0.082 0.813 0.818
10 TBD 0.868 0.225 0.896
11 PBD(2) 0.052 1.000 1.001
12 CRD 1.014 0.000 1.014
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Fig. 3 Simulated forcing index (x‑axis) vs. aggregate expected loss (y‑axis) for 12 restricted randomization procedures for n = 50
Fig. 4 Heatmap of the balance/randomness tradeoff d(i) =
√
{Imb(i)}2 + {FI(i)}2 vs. allocation step ( i = 1, . . . , 50 ) for 12 restricted randomization 
procedures. The procedures are ordered by value of d(50), with smaller values (more red) indicating more optimal performance
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We consider four scenarios of the true mean dif-
ference  � = µE − µC , which correspond to the Null 
case (  = 0 ), and three choices of � > 0 which cor-
respond to Alternative 1 (power ~ 70%), Alternative 2 
(power ~ 80%), and Alternative 3 (power ~ 90%). In all 
cases, n = 50 was used.
Figure  5 summarizes the results of a simulation study 
comparing 12 randomization designs, under 4 models 
for the outcome (M1, M2, M3, and M4), 4 scenarios for 
the mean treatment difference (Null, and Alternatives 1, 
2, and 3), using 3 statistical tests (T1, T2, and T3). The 
operating characteristics of interest are the type I error 
rate under the Null scenario and the power under the 
Alternative scenarios. Each scenario was simulated 
10,000 times, and each randomization-based test was 
computed using L = 10, 000 sequences.
From Fig. 5, under the normal random sampling model 
(M1), all considered randomization designs have similar 
performance: they maintain the type I error rate and have 
similar power, with all tests. In other words, when popu-
lation model assumptions are satisfied, any combination 
of design and analysis should work well and yield reliable 
and consistent results.
Under the “linear trend” model (M2), the designs 
have differential performance. First of all, under the 
Null scenario, only Rand and CRD maintain the type 
I error rate at 5% with all three tests. For TBD, the 
t-test is anticonservative, with type I error rate ~ 20%, 
whereas for nine other procedures the t-test is con-
servative, with type I error rate in the range 0.1–2%. 
At the same time, for all 12 designs the two randomi-
zation-based tests maintain the nominal type I error 
rate at 5%. These results are consistent with some 
previous findings in the literature [67, 68]. As regards 
power, it is reduced significantly compared to the 
normal random sampling scenario. The t-test seems 
to be most affected and the randomization-based 
test using ranks is most robust for a majority of the 
designs. Remarkably, for CRD the power is similar 
with all three tests. This signifies the usefulness of 
randomization-based inference in  situations when 
outcome data are subject to a linear time trend, and 
Fig. 5 Simulated type I error rate and power of 12 restricted randomization procedures. Four models for the data generating mechanism of the 
primary outcome (M1: Normal random sampling; M2: Linear trend; M3: Errors Cauchy; and M4: Selection bias). Four scenarios for the treatment 
mean difference (Null; Alternatives 1, 2, and 3). Three statistical tests (T1: two‑sample t‑test; T2: randomization‑based test using mean difference; T3: 
randomization‑based test using ranks)
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the importance of applying randomization-based tests 
at least as supplemental analyses to likelihood-based 
test procedures.
Under the “Cauchy errors” model (M3), all designs 
perform similarly: the randomization-based tests 
maintain the type I error rate at 5%, whereas the t-test 
deflates the type I error to 2%. As regards power, all 
designs also have similar, consistently degraded perfor-
mance: the t-test is least powerful, and the randomiza-
tion-based test using ranks has highest power. Overall, 
under misspecification of the error distribution a ran-
domization-based test using ranks is most appropriate; 
yet one should acknowledge that its power is still lower 
than expected.
Under the “selection bias” model (M4), the 12 designs 
have differential performance. The only procedure that 
maintained the type I error rate at 5% with all three tests 
was CRD. For eleven other procedures, inflations of the 
type I error were observed. In general, the more ran-
dom the design, the less it was affected by selection bias. 
For instance, the type I error rate for TBD was ~ 6%; for 
Rand, BSD(3), and GBCD(1) it was ~ 7.5%; for GBCD(2) 
and ABCD(2) it was ~ 8–9%; for Efron’s BCD(2/3) it 
was ~ 12.5%; and the most affected design was PBD(2) for 
which the type I error rate was ~ 38–40%. These results 
are consistent with the theory of Blackwell and Hodges 
[28] which posits that TBD is least susceptible to selec-
tion bias within a class of restricted randomization 
designs that force exact balance. Finally, under M4, statis-
tical power is inflated by several percentage points com-
pared to the normal random sampling scenario without 
selection bias.
We performed additional simulations to assess the 
impact of the bias effect ν under selection bias model. 
The same 12 randomization designs and three statisti-
cal tests were evaluated for a trial with n = 50 under the 
Null scenario (  = 0 ), for ν in the range of 0 (no bias) to 
1 (strong bias). Figure S1 in the Supplementary Materials 
shows that for all designs but CRD, the type I error rate is 
increasing in ν , with all three tests. The magnitude of the 
type I error inflation is different across the restricted ran-
domization designs; e.g. for TBD it is minimal, whereas 
for more restrictive designs it may be large, especially 
for ν ≥ 0.4 . PBD(2) is particularly vulnerable: for ν in the 
range 0.4–1, its type I error rate is in the range 27–90% 
(for the nominal α = 5%).
In summary, our Example 1 includes most of the key 
ingredients of the roadmap for assessment of compet-
ing randomization designs which was described in the 
“Methods” section. For the chosen experimental sce-
narios, we evaluated CRD and several restricted rand-
omization procedures, some of which belonged to the 
same class but with different values of the parameter (e.g. 
GBCD with γ = 1, 2, 5 ). We assessed two measures of 
imbalance, two measures of lack of randomness (predict-
ability), and a metric that quantifies balance/randomness 
tradeoff. Based on these criteria, we found that BSD(3) 
provides overall best performance. We also evaluated 
type I error and power of selected randomization proce-
dures under several treatment response models. We have 
observed important links between balance, randomness, 
type I error rate and power. It is beneficial to consider all 
these criteria simultaneously as they may complement 
each other in characterizing statistical properties of ran-
domization designs. In particular, we found that a design 
that lacks randomness, such as PBD with blocks of 2 or 4, 
may be vulnerable to selection bias and lead to inflations 
of the type I error. Therefore, these designs should be 
avoided, especially in open-label studies. As regards sta-
tistical power, since all designs in this example targeted 
1:1 allocation ratio (which is optimal if the outcomes are 
normally distributed and have between-group constant 
variance), they had very similar power of statistical tests 
in most scenarios except for the one with chronological 
bias. In the latter case, randomization-based tests were 
more robust and more powerful than the standard two-
sample t-test under the population model assumption.
Overall, while Example 1 is based on a hypothetical 1:1 
RCT, its true purpose is to showcase the thinking pro-
cess in the application of our general roadmap. The fol-
lowing three examples are considered in the context of 
real RCTs.
Example 2: How can we reduce predictability 
of a randomization procedure and lower the risk 
of selection bias?
Selection bias can arise if the investigator can intelli-
gently guess at least part of the randomization sequence 
yet to be allocated and, on that basis, preferentially 
and strategically assigns study subjects to treatments. 
Although it is generally not possible to prove that a par-
ticular study has been infected with selection bias, there 
are examples of published RCTs that do show some evi-
dence to have been affected by it. Suspect trials are, for 
example, those with strong observed baseline covariate 
imbalances that consistently favor the active treatment 
group [16]. In what follows we describe an example of 
an RCT where the stratified block randomization proce-
dure used was vulnerable to potential selection biases, 
and discuss potential alternatives that may reduce this 
vulnerability.
Etanercept was studied in patients aged 4 to 17  years 
with polyarticular juvenile rheumatoid arthritis [85]. The 
trial consisted of two parts. During the first, open-label 
part of the trial, patients received etanercept twice weekly 
for up to three months. Responders from this initial part 
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of the trial were then randomized, at a 1:1 ratio, in the 
second, double-blind, placebo-controlled part of the trial 
to receive etanercept or placebo for four months or until 
a flare of the disease occurred. The primary efficacy out-
come, the proportion of patients with disease flare, was 
evaluated in the double-blind part. Among the 51 rand-
omized patients, 21 of the 26 placebo patients (81%) with-
drew because of disease flare, compared with 7 of the 25 
etanercept patients (28%), yielding a p-value of 0.003.
Regulatory review by the Food and Drug Administra-
tive (FDA) identified vulnerability to selection biases in 
the study design of the double-blind part and potential 
issues in study conduct. These findings were succinctly 
summarized in [16] (pp.51–52).
Specifically, randomization was stratified by study center 
and number of active joints (≤ 2 vs. > 2, referred to as 
“few” or “many” in what follows), with blocked randomi-
zation within each stratum using a block size of two. Fur-
thermore, randomization codes in corresponding “few” 
and “many” blocks within each study center were mirror 
images of each other. For example, if the first block within 
the “few” active joints stratum of a given center is “placebo 
followed by etanercept”, then the first block within the 
“many” stratum of the same center would be “etanercept 
followed by placebo”. While this appears to be an attempt 
to improve treatment balance in this small trial, unblind-
ing of one treatment assignment may lead to determinis-
tic predictability of three upcoming assignments. While 
the double-blind nature of the trial alleviated this concern 
to some extent, it should be noted that all patients did 
receive etanercept previously in the initial open-label part 
of the trial. Chances of unblinding may not be ignorable if 
etanercept and placebo have immediately evident different 
effects or side effects. The randomized withdrawal design 
was appropriate in this context to improve statistical power 
in identifying efficacious treatments, but the specific ran-
domization procedure used in the trial increased vulner-
ability to selection biases if blinding cannot be completely 
maintained.
FDA review also identified that four patients were ran-
domized from the wrong “few” or “many” strata, in three 
of which (3/51 = 5.9%) it was foreseeable that the treat-
ment received could have been reversed compared to 
what the patient would have received if randomized in 
the correct stratum. There were also some patients ran-
domized out of order. Imbalance in baseline characteris-
tics were observed in age (mean ages of 8.9 years in the 
etanercept arm vs. that of 12.2 years in the placebo arm) 
and corticosteroid use at baseline (50% vs. 24%).
While the authors [85] concluded that “The unequal 
randomization did not affect the study results”, and 
indeed it was unknown whether the imbalance was a 
chance occurrence or in part caused by selection biases, 
the trial could have used better alternative randomization 
procedures to reduce vulnerability to potential selection 
bias. To illustrate the latter point, let us compare pre-
dictability of two randomization procedures – permuted 
block design (PBD) and big stick design (BSD) for several 
values of the maximum tolerated imbalance (MTI). We 
use BSD here for the illustration purpose because it was 
found to provide a very good balance/randomness trade-
off based on our simulations in Example 1. In essence, 
BSD provides the same level of imbalance control as PBD 
but with stronger encryption.
Table  3 reports two metrics for PBD and BSD: pro-
portion of deterministic assignments within a randomi-
zation sequence, and excess correct guess probability. 
The latter metric is the absolute increase in proportion 
of correct guesses for a given procedure over CRD that 
has 50% probability of correct guesses under the “opti-
mal guessing strategy”.1 Note that for MTI = 1, BSD 
is equivalent to PBD with blocks of two. However, by 
increasing MTI, one can substantially decrease predict-
ability. For instance, going from MTI = 1 in the BSD to 
an MTI of 2 or 3 (two bottom rows), the proportion of 
deterministic assignments decreases from 50% to 25% 
and 16.7%, respectively, and excess correct guess prob-
ability decreases from 25% to 12.5% and 8.3%, which is a 
substantial reduction in risk of selection bias. In addition 
to simplicity and lower predictability for the same level 
of MTI control, BSD has another important advantage: 
investigators are not accustomed to it (as they are to the 
PBD), and therefore it has potential for complete elimi-
nation of prediction through thwarting enough early pre-
diction attempts.
Our observations here are also generalizable to other 
MTI randomization methods, such as the maximal pro-
cedure [35], Chen’s designs [38, 39], block urn design 
[40], just to name a few. MTI randomization procedures 
can be also used as building elements for more complex 
stratified randomization schemes [86].
Example 3: How can we mitigate risk of chronological bias?
Chronological bias may occur if a trial recruitment period 
is long, and there is a drift in some covariate over time that 
is subsequently not accounted for in the analysis [29]. To 
mitigate risk of chronological bias, treatment assignments 
should be balanced over time. In this regard, the ICH E9 
guideline has the following statement [31]:
“...Although unrestricted randomisation is an accept-
able approach, some advantages can generally be 
gained by randomising subjects in blocks. This helps 
1 Guess the next allocation as the treatment with fewest allocations in the 
sequence thus far, or make a random guess if the treatment numbers are 
equal.
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to increase the comparability of the treatment groups, 
particularly when subject characteristics may change 
over time, as a result, for example, of changes in 
recruitment policy. It also provides a better guarantee 
that the treatment groups will be of nearly equal size...”
While randomization in blocks of two ensures best bal-
ance, it is highly predictable. In practice, a sensible tradeoff 
between balance and randomness is desirable. In the fol-
lowing example, we illustrate the issue of chronological bias 
in the context of a real RCT.
Altman and Royston [87] gave several examples of clini-
cal studies with hidden time trends. For instance, an RCT 
to compare azathioprine versus placebo in patients with 
primary biliary cirrhosis (PBC) with respect to overall 
survival was an international, double-blind, randomized 
trial including 248 patients of whom 127 received azathi-
oprine and 121 placebo [88]. The study had a recruitment 
period of 7 years. A major prognostic factor for survival 
was the serum bilirubin level on entry to the trial. Alt-
man and Royston [87] provided a cusum plot of log bili-
rubin which showed a strong decreasing trend over time 
– patients who entered the trial later had, on average, 
lower bilirubin levels, and therefore better prognosis. 
Despite that the trial was randomized, there was some 
evidence of baseline imbalance with respect to serum 
bilirubin between azathioprine and placebo groups. The 
analysis using Cox regression adjusted for serum bili-
rubin showed that the treatment effect of azathioprine 
was statistically significant (p = 0.01), with azathioprine 
reducing the risk of dying to 59% of that observed during 
the placebo treatment.
The azathioprine trial [88] provides a very good example 
for illustrating importance of both the choice of a randomi-
zation design and a subsequent statistical analysis. We eval-
uated several randomization designs and analysis strategies 
under the given time trend through simulation. Since we 
did not have access to the patient level data from the aza-
thioprine trial, we simulated a dataset of serum bilirubin 
values from 248 patients that resembled that in the original 
paper (Fig. 1 in [87]); see Fig. 6 below.
For the survival outcomes, we use the following data gen-
erating mechanism [71, 89]: let hi(t, δi) denote the hazard 
function of the ith patient at time t such that
where hc(t) is an unspecified baseline hazard, logHR is 
the true value of the log-transformed hazard ratio, and ui 
is the log serum bilirubin of the ith patient at study entry.
Our main goal is to evaluate the impact of the time 
trend in bilirubin on the type I error rate and power. We 
consider seven randomization designs: CRD, Rand, TBD, 
PBD(2), PBD(4), BSD(3), and GBCD(2). The latter two 
designs were found to be the top two performing proce-
dures based on our simulation results in Example 1 (cf. 
Table 2). PBD(4) is the most commonly used procedure 
in clinical trial practice. Rand and TBD are two designs 
that ensure exact balance in the final treatment numbers. 
CRD is the most random design, and PBD(2) is the most 
balanced design.
To evaluate both type I error and power, we consider 
two values for the true treatment effect: HR = 1 (Null) 
and HR = 0.6 (Alternative). For data analysis, we use 
the Cox regression model, either with or without adjust-
ment for serum bilirubin. Furthermore, we assess two 
approaches to statistical inference: population model-
based and randomization-based. For the sake of sim-
plicity, we let hc(t) ≡ 1 (exponential distribution) and 
assume no censoring when simulating the data.
For each combination of the design, experimental sce-
nario, and data analysis strategy, a trial with 248 patients 
was simulated 10,000 times. Each randomization-based 
test was computed using L = 1, 000 sequences. In each 
simulation, we used the same time trend in serum biliru-
bin as described. Through simulation, we estimated the 
probability of a statistically significant baseline imbalance 
in serum bilirubin between azathioprine and placebo 
groups, type I error rate, and power.
First, we observed that the designs differ with respect 
to their potential to achieve baseline covariate balance 
under the time trend. For instance, probability of a sta-
tistically significant group difference on serum bilirubin 
(two-sided P < 0.05) is ~ 24% for TBD, ~ 10% for CRD, 
~ 2% for GBCD(2), ~ 0.9% for Rand, and ~ 0% for BSD(3), 
PBD(4), and PBD(2).
Second, a failure to adjust for serum bilirubin in the 
analysis can negatively impact statistical inference. 
Table  4 shows the type I error and power of statistical 
analyses unadjusted and adjusted for serum bilirubin, 
using population model-based and randomization-based 
approaches.
If we look at the type I error for the population model-
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Table 3 Predictability of permuted block design (PBD) and big 
stick design (BSD) for different values of maximum tolerated 
imbalance (MTI)




PBD BSD PBD BSD
1 50% 50% 25% 25%
2 33.3% 25% 20.8% 12.5%
3 25% 16.7% 18.3% 8.3%
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Fig. 6 Cusum plot of baseline log serum bilirubin level of 248 subjects from the azathioprine trial, reproduced from Fig. 1 of Altman and Royston 
[87]
Table 4 Type I error and power of seven randomization designs under a time trend
Type I error rate Power
Without adjustment for serum 
bilirubin
With adjustment for serum 
bilirubin




Population model‑based approach to statistical inference
CRD 0.0481 0.0504 0.6114 0.9694
Rand 0.0517 0.0511 0.6193 0.9701
TBD 0.1451 0.0511 0.5856 0.9702
PBD(2) 0.0064 0.0511 0.6540 0.9704
PBD(4) 0.0073 0.0518 0.6612 0.9688
BSD(3) 0.0084 0.0541 0.6547 0.9697
GBCD(2) 0.0185 0.0546 0.6367 0.9699
Randomization‑based approach to statistical inference
CRD 0.049 0.052 0.617 0.970
Rand 0.047 0.048 0.602 0.973
TBD 0.047 0.048 0.367 0.968
PBD(2) 0.048 0.048 0.901 0.969
PBD(4) 0.047 0.047 0.874 0.971
BSD(3) 0.048 0.051 0.860 0.964
GBCD(2) 0.050 0.049 0.803 0.971
Page 19 of 24Berger et al. BMC Med Res Methodol          (2021) 21:168  
and Rand are valid (maintain the type I error rate at 5%), 
whereas TBD is anticonservative (~ 15% type I error) and 
PBD(2), PBD(4), BSD(3), and GBCD(2) are conservative 
(~ 1–2% type I error). These findings are consistent with 
the ones for the two-sample t-test described earlier in the 
current paper, and they agree well with other findings in 
the literature [67]. By contrast, population model-based 
covariate-adjusted analysis is valid for all seven randomi-
zation designs. Looking at the type I error for the rand-
omization-based analyses, all designs yield consistent 
valid results (~ 5% type I error), with or without adjust-
ment for serum bilirubin.
As regards statistical power, unadjusted analyses 
are substantially less powerful then the correspond-
ing covariate-adjusted analysis, for all designs with 
either population model-based or randomization-
based approaches. For the population model-based, 
unadjusted analysis, the designs have ~ 59–65% power, 
whereas than the corresponding covariate-adjusted 
analyses have ~ 97% power. The most striking results are 
observed with the randomization-based approach: the 
power of unadjusted analysis is quite different across 
seven designs: it is ~ 37% for TBD, ~ 60–61% for CRD 
and Rand, ~ 80–87% for BCD(3), GBCD(2), and PBD(4), 
and it is ~ 90% for PBD(2). Thus, PBD(2) is the most 
powerful approach if a time trend is present, statistical 
analysis strategy is randomization-based, and no adjust-
ment for time trend is made. Furthermore, randomiza-
tion-based covariate-adjusted analyses have ~ 97% power 
for all seven designs. Remarkably, the power of covari-
ate-adjusted analysis is identical for population model-
based and randomization-based approaches.
Overall, this example highlights the importance of 
covariate-adjusted analysis, which should be straight-
forward if a covariate affected by a time trend is known 
(e.g. serum bilirubin in our example). If a covariate is 
unknown or hidden, then unadjusted analysis following 
a conventional test may have reduced power and dis-
torted type I error (although the designs such as CRD 
and Rand do ensure valid statistical inference). Alter-
natively, randomization-based tests can be applied. The 
resulting analysis will be valid but may be potentially 
less powerful. The degree of loss in power following 
randomization-based test depends on the randomiza-
tion design: designs that force greater treatment bal-
ance over time will be more powerful. In fact, PBD(2) is 
shown to be most powerful under such circumstances; 
however, as we have seen in Example 1 and Example 2, 
a major deficiency of PBD(2) is its vulnerability to selec-
tion bias. From Table  4, and taking into account the 
earlier findings in this paper, BSD(3) seems to provide 
a very good risk mitigation strategy against unknown 
time trends.
Example 4: How do we design an RCT with a very small 
sample size?
In our last example, we illustrate the importance of the 
careful choice of randomization design and subsequent 
statistical analysis in a nonstandard RCT with small sam-
ple size. Due to confidentiality and because this study is 
still in conduct, we do not disclose all details here except 
for that the study is an ongoing phase II RCT in a very 
rare and devastating autoimmune disease in children.
The study includes three periods: an open-label single-
arm active treatment for 28 weeks to identify treatment 
responders (Period 1), a 24-week randomized treatment 
withdrawal period to primarily assess the efficacy of 
the active treatment vs. placebo (Period 2), and a 3-year 
long-term safety, open-label active treatment (Period 3). 
Because of a challenging indication and the rarity of the 
disease, the study plans to enroll up to 10 male or female 
pediatric patients in order to randomize 8 patients (4 per 
treatment arm) in Period 2 of the study. The primary end-
point for assessing the efficacy of active treatment versus 
placebo is the proportion of patients with disease flare 
during the 24-week randomized withdrawal phase. The 
two groups will be compared using Fisher’s exact test. In 
case of a successful outcome, evidence of clinical efficacy 
from this study will be also used as part of a package to 
support the claim for drug effectiveness.
Very small sample sizes are not uncommon in clinical 
trials of rare diseases [90, 91]. Naturally, there are several 
methodological challenges for this type of study. A major 
challenge is generalizability of the results from the RCT 
to a population. In this particular indication, no approved 
treatment exists, and there is uncertainty on disease epi-
demiology and the exact number of patients with the 
disease who would benefit from treatment (patient hori-
zon). Another challenge is the choice of the randomiza-
tion procedure and the primary statistical analysis. In 
this study, one can enumerate upfront all 25 possible out-
comes: {0, 1, 2, 3, 4} responders on active treatment, and 
{0, 1, 2, 3, 4} responders on placebo, and create a chart 
quantifying the level of evidence (p-value) for each exper-
imental outcome, and the corresponding decision. Before 
the trial starts, a discussion with the regulatory agency is 
warranted to agree upon on what level of evidence must 
be achieved in order to declare the study a “success”.
Let us perform a hypothetical planning for the given 
study. Suppose we go with a standard population-based 
approach, for which we test the hypothesis H0 : pE = pC 
vs. H0 : pE > pC (where pE and pC stand for the true 
success rates for the experimental and control group, 
respectively) using Fisher’s exact test. Table  5 provides 
1-sided p-values of all possible experimental outcomes. 
One could argue that a p-value < 0.1 may be viewed as a 
convincing level of evidence for this study. There are only 
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3 possibilities that can lead to this outcome: 3/4 vs. 0/4 
successes (p = 0.0714); 4/4 vs. 0/4 successes (p = 0.0143); 
and 4/4 vs. 1/4 successes (p = 0.0714). For all other out-
comes, p ≥ 0.2143, and thus the study would be regarded 
as a “failure”.
Now let us consider a randomization-based inference 
approach. For illustration purposes, we consider four 
restricted randomization procedures—Rand, TBD, PBD(4), 
and PBD(2)—that exactly achieve 4:4 allocation. These pro-
cedures are legitimate choices because all of them provide 
exact sample sizes (4 per treatment group), which is essen-






 unique sequences though with differ-
ent probabilities of observing each sequence. For Rand, 
these sequences are equiprobable, whereas for TBD, some 
sequences are more likely than others. For PBD(2b ), the 





 , where B = n/2b is 
the number of blocks of length 2b for a trial of size n (in our 
example n = 8 ). This results in in a reference set of 24 = 16 
unique sequences with equal probability of 1/16 for PBD(2), 
and of 62 = 36 unique sequences with equal probability of 
1/36 for PBD(4).
In practice, the study statistician picks a treatment 
sequence at random from the reference set according to 
the chosen design. The details (randomization seed, cho-
sen sequence, etc.) are carefully documented and kept 
confidential. For the chosen sequence and the observed 
outcome data, a randomization-based p-value is the sum 
of probabilities of all sequences in the reference set that 
yield the result at least as large in favor of the experimen-
tal treatment as the one observed. This p-value will depend 
on the randomization design, the observed randomization 
sequence and the observed outcomes, and it may also be 
different from the population-based analysis p-value.
To illustrate this, suppose the chosen randomiza-
tion sequence is CEECECCE (C stands for control and 
E stands for experimental), and the observed responses 
Table 5 All possible outcomes, p-values, and corresponding decisions for an RCT with n = 8 patients (4 per treatment arm) with 
Fisher’s exact test
a  F Declare study a failure, S Declare study a success
Number of responders Difference in proportions (Experimental 
vs. Control)




0/4 0/4 0 1.0 F
1/4 1/4 0 0.7857 F
2/4 2/4 0 0.7571 F
3/4 3/4 0 0.7857 F
4/4 4/4 0 1.0 F
1/4 0/4 0.25 0.5 F
2/4 0/4 0.50 0.2143 F
3/4 0/4 0.75 0.0714 S
4/4 0/4 1 0.0143 S
0/4 1/4 ‑0.25 1.0 F
0/4 2/4 ‑0.50 1.0 F
0/4 3/4 ‑0.75 1.0 F
0/4 4/4 ‑1 1.0 F
2/4 1/4 0.25 0.5 F
3/4 1/4 0.50 0.2429 F
4/4 1/4 0.75 0.0714 S
1/4 2/4 ‑0.25 0.9286 F
1/4 3/4 ‑0.50 0.9857 F
1/4 4/4 ‑0.75 1.0 F
3/4 2/4 0.25 0.5 F
4/4 2/4 0.50 0.2143 F
2/4 3/4 ‑0.25 0.9286 F
2/4 4/4 ‑0.50 1.0 F
4/4 3/4 0.25 0.5 F
3/4 4/4 ‑0.25 1.0 F
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are FSSFFFFS (F stands for failure and S stands for suc-
cess). Thus, we have 3/4 successes on experimental and 
0/4 successes on control. Then, the randomization-based 
p-value is 0.0714 for Rand; 0.0469 for TBD, 0.1250 for 
PBD(2); 0.0833 for PBD(4); and it is 0.0714 for the pop-
ulation-based analysis. The coincidence of the randomi-
zation-based p-value for Rand and the p-value of the 
population-based analysis is not surprising. Fisher’s exact 
test is a permutation test and in the case of Rand as ran-
domization procedure, the p-value of a permutation test 
and of a randomization test are always equal. However, 
despite the numerical equality, we should be mindful of 
different assumptions (population/randomization model).
Likewise, randomization-based p-values can be derived 
for other combinations of observed randomization 
sequences and responses. All these details (the chosen 
randomization design, the analysis strategy, and cor-
responding decisions) would have to be fully specified 
upfront (before the trial starts) and agreed upon by both 
the sponsor and the regulator. This would remove any 
ambiguity when the trial data become available.
As the example shows, the level of evidence in the 
randomization-based inference approach depends on 
the chosen randomization procedure and the resulting 
decisions may be different depending on the specific pro-
cedure. For instance, if the level of significance is set to 
10% as a criterion for a “successful trial”, then with the 
observed data (3/4 vs. 0/4), there would be a significant 
test result for TBD, Rand, PBD(4), but not for PBD(2).
Conclusions
Summary and discussion
Randomization is the foundation of any RCT involving 
treatment comparison. Randomization is not a single 
technique, but a very broad class of statistical methodol-
ogies for design and analysis of clinical trials [10]. In this 
paper, we focused on the randomized controlled two-arm 
trial designed with equal allocation, which is the gold 
standard research design to generate clinical evidence in 
support of regulatory submissions. Even in this relatively 
simple case, there are various restricted randomization 
procedures with different probabilistic structures and dif-
ferent statistical properties, and the choice of a randomi-
zation design for any RCT must be made judiciously.
For the 1:1 RCT, there is a dual goal of balancing treat-
ment assignments while maintaining allocation ran-
domness. Final balance in treatment totals frequently 
maximizes statistical power for treatment comparison. It is 
also important to maintain balance at intermediate steps 
during the trial, especially in long-term studies, to miti-
gate potential for chronological bias. At the same time, a 
procedure should have high degree of randomness so that 
treatment assignments within the sequence are not easily 
predictable; otherwise, the procedure may be vulnerable 
to selection bias, especially in open-label studies. While 
balance and randomness are competing criteria, it is pos-
sible to find restricted randomization procedures that 
provide a sensible tradeoff between these criteria, e.g. the 
MTI procedures, of which the big stick design (BSD) [37] 
with a suitably chosen MTI limit, such as BSD(3), has very 
appealing statistical properties. In practice, the choice of a 
randomization procedure should be made after a system-
atic evaluation of different candidate procedures under 
different experimental scenarios for the primary outcome, 
including cases when model assumptions are violated.
In our considered examples we showed that the choice 
of randomization design, data analytic technique (e.g. 
parametric or nonparametric model, with or without 
covariate adjustment), and the decision on whether to 
include randomization in the analysis (e.g. randomiza-
tion-based or population model-based analysis) are all 
very important considerations. Furthermore, these exam-
ples highlight the importance of using randomization 
designs that provide strong encryption of the randomiza-
tion sequence, importance of covariate adjustment in the 
analysis, and the value of statistical thinking in nonstand-
ard RCTs with very small sample sizes and small patient 
horizon. Finally, in this paper we have discussed rand-
omization-based tests as robust and valid alternatives to 
likelihood-based tests. Randomization-based inference is 
a useful approach in clinical trials and should be consid-
ered by clinical researchers more frequently [14].
Further topics on randomization
Given the breadth of the subject of randomization, many 
important topics have been omitted from the current 
paper. Here we outline just a few of them.
In this paper, we have focused on the 1:1 RCT. How-
ever, clinical trials may involve more than two treat-
ment arms. Extensions of equal randomization to the 
case of multiple treatment arms is relatively straight-
forward for many restricted randomization procedures 
[10]. Some trials with two or more treatment arms use 
unequal allocation (e.g. 2:1). Randomization procedures 
with unequal allocation ratios require careful considera-
tion. For instance, an important and desirable feature is 
the allocation ratio preserving property (ARP). A rand-
omization procedure targeting unequal allocation is said 
to be ARP, if at each allocation step the unconditional 
probability of a particular treatment assignment is the 
same as the target allocation proportion for this treat-
ment [92]. Non-ARP procedures may have fluctuations 
in the unconditional randomization probability from 
allocation to allocation, which may be problematic [93]. 
Fortunately, some randomization procedures naturally 
possess the ARP property, and there are approaches to 
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correct for a non-ARP deficiency – these should be con-
sidered in the design of RCTs with unequal allocation 
ratios [92–94].
In many RCTs, investigators may wish to prospec-
tively balance treatment assignments with respect to 
important prognostic covariates. For a small number of 
categorical covariates one can use stratified randomi-
zation by applying separate MTI randomization proce-
dures within strata [86]. However, a potential advantage 
of stratified randomization decreases as the number of 
stratification variables increases [95]. In trials where 
balance over a large number of covariates is sought and 
the sample size is small or moderate, one can consider 
covariate-adaptive randomization procedures that 
achieve balance within covariate margins, such as the 
minimization procedure [96, 97], optimal model-based 
procedures [46], or some other covariate-adaptive ran-
domization technique [98]. To achieve valid and pow-
erful results, covariate-adaptive randomization design 
must be followed by covariate-adjusted analysis [99]. 
Special considerations are required for covariate-adap-
tive randomization designs with more than two treat-
ment arms and/or unequal allocation ratios [100].
In some clinical research settings, such as trials for 
rare and/or life threatening diseases, there is a strong 
ethical imperative to increase the chance of a trial par-
ticipant to receive an empirically better treatment. 
Response-adaptive randomization (RAR) has been 
increasingly considered in practice, especially in oncol-
ogy [101, 102]. Very extensive methodological research 
on RAR has been done [103, 104]. RAR is increasingly 
viewed as an important ingredient of complex clinical 
trials such as umbrella and platform trial designs [105, 
106]. While RAR, when properly applied, has its merit, 
the topic has generated a lot of controversial discussions 
over the years [107–111]. Amid the ongoing COVID-19 
pandemic, RCTs evaluating various experimental treat-
ments for critically ill COVID-19 patients do incorpo-
rate RAR in their design; see, for example, the I-SPY 
COVID-19 trial (https:// clini caltr ials. gov/ ct2/ show/ 
NCT04 488081).
Randomization can also be applied more broadly than in 
conventional RCT settings where randomization units are 
individual subjects. For instance, in a cluster randomized 
trial, not individuals but groups of individuals (clusters) 
are randomized among one or more interventions or 
the control [112]. Observations from individuals within 
a given cluster cannot be regarded as independent, and 
special statistical techniques are required to design and 
analyze cluster-randomized experiments. In some clini-
cal trial designs, randomization is applied within subjects. 
For instance, the micro-randomized trial (MRT) is a novel 
design for development of mobile treatment interventions 
in which randomization is applied to select different treat-
ment options for individual participants over time to opti-
mally support individuals’ health behaviors [113].
Finally, beyond the scope of the present paper are the 
regulatory perspectives on randomization and practical 
implementation aspects, including statistical software 
and information systems to generate randomization 
schedules in real time. We hope to cover these topics in 
subsequent papers.
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